SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	<u> </u>	013			of the investment company Act of	10-10				
1. Name and Address of Reporting Person* Frazier Healthcare V, LP		2. Date of Event Requiring Statement (Month/Day/Year) 10/24/2006			3. Issuer Name and Ticker or Trading Symbol <u>CADENCE PHARMACEUTICALS INC</u> [CADX]					
(Last) (First) (Middle) 601 UNION STREET, SUITE 3200			10/2 1/2000		4. Relationship of Reporting Pe (Check all applicable) Director		5. If Amendment, Date of Original Filed (Month/Day/Year)			
					Officer (give title	Other (spe		ndividual or Joint plicable Line)	/Group Filing (Check	
(Street) SEATTLE WA 981	01				below)	below)		Form filed b	y One Reporting Person y More than One erson	
(City) (State) (Zip)	Tabla I. A		Deview						
		Table I - N	ion	-Deriva	ative Securities Benefici	-				
1. Title of Security (Instr. 4)					2. Amount of Securities 3. Owners Beneficially Owned (Instr. 4) Form: Dir or Indirec (Instr. 5)		t (D) (Inst	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)			3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversio or Exercis Price of		6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Date Exercisable			Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)		
Series A-3 Preferred Stock ⁽¹⁾	tock ⁽¹⁾ (2)		(3)		Common Stock	2,500,000 ⁽⁴⁾	(5)	I	By Frazier Healthcare V, LP ⁽⁶⁾	
1. Name and Address of Reporting Person <u>Frazier Healthcare V, LP</u>	on [*]									
(Last) (First)	(Midc	lle)	_							
601 UNION STREET, SUITE 320		-,								
(Street) SEATTLE WA	9810	98101								
(City) (State)	(Zip)	(Zip)								
1. Name and Address of Reporting Person <u>FHM V, LP</u>	on [*]									
(Last) (First)										
601 UNION STREET, SUITE 320)0									
(Street) SEATTLE WA	98101									
(City) (State)	y) (State) (Zip)									
1. Name and Address of Reporting Person <u>FHM V, LLC</u>	on*									
(Last)(First)(Middle)601 UNION STREET, SUITE 3200										
(Street) SEATTLE WA	9810)1								
(City) (State)	(State) (Zip)									

Explanation of Responses:

1. These securities will automatically convert into Common Stock upon the closing of Cadence Pharmaceutical, Inc.'s initial public offering.

2. Immediately convertible.

3. Not applicable.

4. Reflects a 1-for-4 reverse stock split, pursuant to which each share of Preferred Stock became convertible into 1/4 of a share of Common Stock.

5. 4-for-1.

6. The securities are owned directly by Frazier Healthcare V, LP, the designated filer. The general partner of Frazier Healthcare V, LP is FHM V, LP, a joint filter. FHM V, LLC, also a joint filer, is the general partner of FHM V, LP, FHM V, LP and FHM V, LLC disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein and this report shall not be deemed an admission for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 99.1 - Joint Filer Information

 Frazier Healthcare V, LP by

 FHM V, LP, its General Partner

 by FHM V, LLC, its General
 10/24/2006

 Partner /s/ Thomas S. Hodge,

 Chief Operating Officer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 Joint Filer Information

Name: Address: FHM V, LP 601 Union Street, Suite 3200 Seattle, WA 98101

Designated Filer:

Frazier Healthcare V, LP

Issuer & Ticker Symbol:

Cadence Pharmaceuticals, Inc. (CADX)

Date of Event Requiring Statement:

October 24, 2006

FHM V, LP By: FHM V, LLC, its General Partner

By: <u>/s/ Thomas S. Hodge</u> Thomas S. Hodge, Chief Operating Officer

Name: Address: FHM V, LLC 601 Union Street, Suite 3200 Seattle, WA 98101

Designated Filer:

Frazier Healthcare V, LP

Cadence Pharmaceuticals, Inc. (CADX)

Issuer & Ticker Symbol:

Date of Event Requiring Statement:

October 24, 2006

FHM V, LLC

By: <u>/s/ Thomas S. Hodge</u> Thomas S. Hodge, Chief Operating Officer